Sibanye-Stillwater has entered a strategic partnership with the South African Nuclear Energy Corporation to develop radioactive isotopes derived from platinum group metals, marking a shift towards medical applications for minerals traditionally linked to industrial demand.
The collaboration centres on the production of Palladium-103, a nuclide widely used in brachytherapy for treating localised cancers, particularly prostate tumours.
The technique involves implanting radioactive sources directly into affected tissue, enabling targeted radiation delivery while reducing exposure to surrounding healthy cells. This approach has gained traction within precision oncology as healthcare systems seek more effective and less invasive treatment options.
The process relies on irradiating rhodium in a nuclear reactor to alter its atomic structure, producing Palladium-103. While rhodium has historically been used in catalytic converters and other industrial applications, the partnership reflects a broader effort to reposition platinum group metals within high-value sectors such as healthcare and advanced technologies.
Necsa already plays a significant role in global nuclear medicine supply chains, producing isotopes used in the diagnosis and treatment of cancer and cardiovascular conditions. Its products are distributed internationally through regulated channels, with demand for radiopharmaceuticals continuing to grow. Industry estimates suggest the global nuclear medicine market is expanding at a steady pace, driven by rising cancer incidence and increased adoption of targeted therapies.
The initial phase of the project will focus on testing and validating whether locally sourced rhodium meets the stringent purity requirements for isotope production. This includes refining processes to produce high-purity Palladium-103 suitable for clinical use. Establishing a domestic supply chain for such isotopes could reduce reliance on imports and position South Africa as a more integrated player in the radiopharmaceutical sector.
A subsequent phase is expected to extend research into additional applications involving rhodium and other platinum group metals. This reflects a growing interest in the potential of these materials in medical and technological fields beyond their traditional uses. For mining companies, such diversification is increasingly important as demand patterns shift, particularly in the automotive sector where the transition away from internal combustion engines is expected to reduce long-term consumption of certain PGMs.
For Sibanye-Stillwater, the initiative forms part of a broader strategy to identify alternative demand streams for its metals portfolio. The company has been investing in research and development aimed at expanding the application base of PGMs, seeking to offset structural changes in established markets. The move into nuclear medicine aligns with this approach, linking resource extraction to high-value downstream industries.
From a policy perspective, the partnership also supports efforts to strengthen South Africa’s capabilities in advanced manufacturing and scientific research. By combining mining output with nuclear expertise, the project contributes to a more integrated value chain, with potential spillover effects in skills development and technology transfer. It also reinforces the role of state-owned entities in facilitating industrial innovation through collaboration with the private sector.
The development comes at a time when global competition in radiopharmaceuticals is intensifying, with countries investing in production capacity and research infrastructure to secure supply and capture market share. South Africa’s existing capabilities, anchored by Necsa’s facilities, provide a foundation for expansion, although scaling production to meet international demand will require sustained investment and regulatory alignment.
As the project progresses, its success will depend on meeting stringent clinical and regulatory standards, as well as establishing reliable distribution channels. If achieved, the initiative could open a new avenue for South Africa’s mineral resources, linking them directly to healthcare outcomes and positioning the country within a specialised segment of the global medical economy.